Skip to content

RESPONSE GENETICS INC

Delisted

CIK 1124608fmd_03RZQF878H4W40QY4KA6XGY73HManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard

Coverage: Jan 01, 2010 to Mar 31, 2015, 20 periods

Latest annual · FY2014

Millions
Total revenues
17
Gross profit
7
Operating income
(13)
Net income
(14)
Free cash flow
(14)

Latest quarter · Q1 FY2015

Millions
Total revenues
4
Gross profit
1
Operating income
(4)
Net income
(4)
Free cash flow
(2)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2011 to FY2014
-9.6%

RESPONSE GENETICS INC financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2014FY2013ChangeSource
Revenue$16.7 million$19.8 million-15.6%10-K 2015-03-31 · proof
Gross profit$6.7 million$9.3 million-28.2%10-K 2015-03-31 · proof
Operating income-$13 million-$7.9 million10-K 2015-03-31 · proof
Net income-$13.7 million-$8 million10-K 2015-03-31 · proof
Cash from operating activities-$14.3 million-$6.5 million10-K 2015-03-31 · proof
Free cash flow-$14.3 million-$6.7 million10-K 2015-03-31 · proof
Total assets$13.4 million$18.1 million-25.5%10-K 2015-03-31 · proof
Total liabilities$14.6 million$6.8 million+115%10-K 2015-03-31 · proof
Cash and cash equivalents$2.2 million$8.1 million-72.7%10-K 2015-03-31 · proof
What was RESPONSE GENETICS INC's revenue in fiscal 2014?
RESPONSE GENETICS INC reported revenue of $16.7 million for fiscal 2014 (the year ended Dec 31, 2014), against $19.8 million the year before (-15.6%). Source: the 10-K filed with the SEC on Mar 31, 2015. SEC
What was RESPONSE GENETICS INC's gross profit in fiscal 2014?
RESPONSE GENETICS INC reported gross profit of $6.7 million for fiscal 2014 (the year ended Dec 31, 2014), against $9.3 million the year before (-28.2%). Source: the 10-K filed with the SEC on Mar 31, 2015. SEC
What was RESPONSE GENETICS INC's operating income in fiscal 2014?
RESPONSE GENETICS INC reported operating income of -$13 million for fiscal 2014 (the year ended Dec 31, 2014), against -$7.9 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2015. SEC
What was RESPONSE GENETICS INC's net income in fiscal 2014?
RESPONSE GENETICS INC reported net income of -$13.7 million for fiscal 2014 (the year ended Dec 31, 2014), against -$8 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2015. SEC
What was RESPONSE GENETICS INC's cash from operating activities in fiscal 2014?
RESPONSE GENETICS INC reported cash from operating activities of -$14.3 million for fiscal 2014 (the year ended Dec 31, 2014), against -$6.5 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2015. SEC
What was RESPONSE GENETICS INC's free cash flow in fiscal 2014?
RESPONSE GENETICS INC reported free cash flow of -$14.3 million for fiscal 2014 (the year ended Dec 31, 2014), against -$6.7 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2015. SEC
What are RESPONSE GENETICS INC's total assets?
As of Dec 31, 2014, RESPONSE GENETICS INC reported total assets of $13.4 million, against $18.1 million a year earlier (-25.5%). Source: the 10-K filed with the SEC on Mar 31, 2015. SEC
What are RESPONSE GENETICS INC's total liabilities?
As of Dec 31, 2014, RESPONSE GENETICS INC reported total liabilities of $14.6 million, against $6.8 million a year earlier (+115%). Source: the 10-K filed with the SEC on Mar 31, 2015. SEC
What are RESPONSE GENETICS INC's cash and cash equivalents?
As of Dec 31, 2014, RESPONSE GENETICS INC reported cash and cash equivalents of $2.2 million, against $8.1 million a year earlier (-72.7%). Source: the 10-K filed with the SEC on Mar 31, 2015. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1124608&period_type=annual&limit=5"

Information only, not investment advice.